Comparative Pharmacology
Head-to-head clinical analysis: ENTOCORT EC versus FLOVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENTOCORT EC versus FLOVENT.
ENTOCORT EC vs FLOVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Budesonide is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to anti-inflammatory effects via inhibition of inflammatory mediators such as cytokines and prostaglandins.
Fluticasone propionate is a synthetic corticosteroid with anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory transcription factors (e.g., NF-κB) and increased synthesis of lipocortin-1, which reduces phospholipase A2 activity and subsequent release of arachidonic acid metabolites (prostaglandins, leukotrienes). In the lungs, it decreases airway inflammation by reducing eosinophil infiltration, mast cell degranulation, and cytokine release.
9 mg orally once daily in the morning for up to 8 weeks.
Inhalation aerosol: 88-880 mcg twice daily; typical starting dose: 88 mcg twice daily. Max: 880 mcg twice daily. Oral inhalation powder: 100-1000 mcg twice daily; typical starting: 100 mcg twice daily. Max: 1000 mcg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours; clinically, the extended intestinal release formulation maintains local activity despite short systemic half-life.
Approximately 14.4 hours (range 7.8–24.6 hours) for the inhaled route; supports twice-daily dosing; prolonged in hepatic impairment.
Primarily fecal (60-70%) with minimal renal excretion (<10%); extensively metabolized hepatically, metabolites excreted in bile and feces.
Primarily hepatic metabolism (CYP3A4) with fecal excretion of metabolites; renal excretion accounts for <5% of the dose as unchanged drug and metabolites combined.
Category C
Category C
Corticosteroid
Corticosteroid